Skip to main content
Clinical Trials/NCT02366299
NCT02366299
Withdrawn
Phase 4

Comparison of Sedative Effects of Dexmedetomidine and Propofol on the Clinical Course of Delirium and Neuroinflammation in Patients With SIRS.

Moscow Regional Research and Clinical Institute (MONIKI)0 sitesFebruary 2015

Overview

Phase
Phase 4
Intervention
Dexmedetomidine
Conditions
Delirium
Sponsor
Moscow Regional Research and Clinical Institute (MONIKI)
Primary Endpoint
CAM-ICU scale
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

Assessment of sedative effects of dexmedetomidine and propofol on the clinical course of delirium and neuroinflammation in patients with SIRS using CAM-ICU scale and protein S100b in serum.

Registry
clinicaltrials.gov
Start Date
February 2015
End Date
December 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Moscow Regional Research and Clinical Institute (MONIKI)
Responsible Party
Principal Investigator
Principal Investigator

Valery V. Likhvantsev, Professor

senior researcher

Moscow Regional Research and Clinical Institute (MONIKI)

Eligibility Criteria

Inclusion Criteria

  • presence of delirium

Exclusion Criteria

  • presence of Alzheimer's disease
  • any mental disorder
  • presence of cancer

Arms & Interventions

dexmedetomidine

Treatment of delirium by dexmedetomidine i.v. infusion

Intervention: Dexmedetomidine

propofol

Treatment of delirium by propofol i.v. infusion

Intervention: Propofol

Outcomes

Primary Outcomes

CAM-ICU scale

Time Frame: up to 5 days

Similar Trials